Search / Trial NCT00002171

A Study of Viracept in HIV-Positive Women

Launched by AGOURON PHARMACEUTICALS · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

Placebos Drug Therapy, Combination Stavudine Hiv Protease Inhibitors Lamivudine Nelfinavir Anti Hiv Agents

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria
  • Patients must have:
  • HIV infection.
  • CD4 T cell count \<= 400 cells/mm3.
  • Exclusion Criteria
  • Prior Medication:
  • Excluded:
  • Prior therapy or less than 1 month of therapy with d4T and/or 3TC.
  • Prior protease inhibitor therapy.

About Agouron Pharmaceuticals

Agouron Pharmaceuticals is a biopharmaceutical company dedicated to advancing innovative therapies for the treatment of serious medical conditions. With a strong focus on research and development, Agouron leverages cutting-edge science and technology to discover and optimize novel drug candidates. The company is committed to improving patient outcomes through rigorous clinical trials and collaborations with healthcare professionals. By prioritizing safety and efficacy, Agouron aims to deliver transformative solutions that address unmet medical needs and enhance the quality of life for patients around the world.

Locations

Birmingham, Alabama, United States

Los Angeles, California, United States

Houston, Texas, United States

New Orleans, Louisiana, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials